Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Zabedosertib
- DrugBank Accession Number
- DB18767
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Zabedosertib (DB18767)
- Weight
- Average: 470.47
Monoisotopic: 470.123560835 - Chemical Formula
- C20H21F3N4O4S
- Synonyms
- 2-pyridinecarboxamide, n-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2h-indazol-5-yl)-6-(trifluoromethyl)-
- N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2h-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide
- N-(6-(2-hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2h-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide
- External IDs
- BAY 1834845
- BAY-1834845
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AInterleukin-1 receptor-associated kinase 4 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N1GRK350ZM
- CAS number
- 1931994-81-8
- InChI Key
- OQAMEEFUUFJZRS-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H21F3N4O4S/c1-19(2,29)13-10-15-12(11-27(26-15)7-8-32(3,30)31)9-16(13)25-18(28)14-5-4-6-17(24-14)20(21,22)23/h4-6,9-11,29H,7-8H2,1-3H3,(H,25,28)
- IUPAC Name
- SMILES
- CC(C)(O)C1=CC2=NN(CCS(C)(=O)=O)C=C2C=C1NC(=O)C1=CC=CC(=N1)C(F)(F)F
References
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Atopic Dermatitis 1 somestatus stop reason just information to hide 1 Completed Basic Science Immune Mediated Inflammatory Diseases 1 somestatus stop reason just information to hide 1 Completed Basic Science Pelvic Inflammatory Disease (PID) 1 somestatus stop reason just information to hide 1 Completed Other Inflammation 1 somestatus stop reason just information to hide 1 Completed Treatment Healthy Volunteers (HV) / Psoriasis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways (PubMed:17878374). Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections.
- Specific Function
- ATP binding
- Gene Name
- IRAK4
- Uniprot ID
- Q9NWZ3
- Uniprot Name
- Interleukin-1 receptor-associated kinase 4
- Molecular Weight
- 51529.285 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at June 19, 2024 17:49 / Updated at August 27, 2024 19:17